1. Gilead says remdesivir cut risk of COVID patient death in clinical trial — BioNTech-Pfizer COVID vaccine expected to be ready for approval by year end — LEO Pharma eyeing 2021 launch for Dupixent rival — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Merck joins pharma giants in lowering drug prices

Discussion in 'Merck' started by RobertPhillips900, Jul 20, 2018 at 8:28 AM.

  1. RobertPhillips900

    Joined:
    Aug 29, 2016
    Messages:
    51
    Likes Received:
    0

  2. anonymous

    anonymous Guest

    Well, there ya go. Lower prices = lower profit margins. Quickest way to deal with that? Chop Heads!!
     
  3. anonymous

    anonymous Guest

    The Social Justice Warrior CEO, and his actions, left Merck nowhere to go on this.

    Wow - you sure look like a smart SOB now Kenny! I bet you'll still get some sort of compensation for your hard work on the SJW front, fool. Even though you gave away what little leverage the company may have had.
     
  4. anonymous

    anonymous Guest

  5. anonymous

    anonymous Guest

    Better we do it ourselves than have the don’t do it for us. The gravy train is over. We’ve been gouging patients for years; time to pay the piper.
     
  6. anonymous

    anonymous Guest

    What leverage? The world will get along very nicely without Merck drugs.
    Entitled turds like you will never learn until it affects you or your family.